Aardvark Therapeutics Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
28
- Stock Symbol
-
AARD
- Investments
-
2
- Share Price
-
$1.33
- (As of Friday Closing)
Aardvark Therapeutics General Information
Description
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Contact Information
Website
www.aardvarktherapeutics.comCorporate Office
- 4370 La Jolla Village Drive
- Suite 1050
- San Diego, CA 92122
- United States
Corporate Office
- 4370 La Jolla Village Drive
- Suite 1050
- San Diego, CA 92122
- United States
Aardvark Therapeutics Stock Performance
As of 13-Nov-2026, Aardvark Therapeutics’s stock price is $1.33. Its current market cap is $29.1M with 21.9M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.33 | $1.52 | $0.93 - $16.60 | $29.1M | 21.9M | 618K | -$3.33 |
Aardvark Therapeutics Financials Summary
As of 30-Sep-2026, Aardvark Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 42,140 | 159,969 | ||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (75,965) | (62,694) | (22,986) | (8,631) |
| Net Income | (72,759) | (57,591) | (20,588) | (7,208) |
| Total Assets | 64,800 | 117,181 | 77,507 | 10,536 |
| Total Debt | 572 | 441 | 779 | 162 |
Aardvark Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Aardvark Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Aardvark Therapeutics Comparisons
Industry
Financing
Details
Aardvark Therapeutics Competitors (49)
One of Aardvark Therapeutics’s 49 competitors is Galectin Therapeutics, a Corporation company based in Norcross, GA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Galectin Therapeutics | Corporation | Norcross, GA | ||||
| Nimbus Therapeutics | Venture Capital-Backed | Boston, MA | ||||
| Altimmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Minerva Neurosciences | Formerly VC-backed | Burlington, MA |
Aardvark Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aardvark Therapeutics Patents
Aardvark Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026213061-A1 | Methods for treating muscle loss and/or increasing muscle mass | Pending | 31-Mar-2025 | ||
| WO-2026085322-A1 | Isoflavonoid formulations and methods of use | Pending | 18-Oct-2024 | ||
| WO-2026030548-A1 | Formulations comprising a denatonium salt for preventing malicious drug use | Pending | 01-Aug-2024 | ||
| WO-2025217435-A1 | Pharmaceutical formulations containing phenylbutyrate and methods thereof | Pending | 12-Apr-2024 | ||
| US-20250049924-A1 | Abuse-deterrent pharmaceutical composition with aversion properties | Pending | 27-Apr-2022 | A61K47/186 |
Aardvark Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aardvark Therapeutics Investments (2)
Aardvark Therapeutics’s most recent deal was a Corporate Asset Purchase with MEI Pharma (Rights, Title, Interest and Certain Assets Related to ME-344) for . The deal was made on 22-Oct-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| MEI Pharma (Rights, Title, Interest and Certain Assets Related to ME-344) | 22-Oct-2024 | Corporate Asset Purchase | Buildings and Property | ||
| GRI Bio (ADAIR Asset) | 23-Aug-2023 | Corporate Asset Purchase | Buildings and Property |
Aardvark Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Aardvark Therapeutics FAQs
-
When was Aardvark Therapeutics founded?
Aardvark Therapeutics was founded in 2017.
-
Where is Aardvark Therapeutics headquartered?
Aardvark Therapeutics is headquartered in San Diego, CA.
-
What is the size of Aardvark Therapeutics?
Aardvark Therapeutics has 28 total employees.
-
What industry is Aardvark Therapeutics in?
Aardvark Therapeutics’s primary industry is Drug Discovery.
-
Is Aardvark Therapeutics a private or public company?
Aardvark Therapeutics is a Public company.
-
What is Aardvark Therapeutics’s stock symbol?
The ticker symbol for Aardvark Therapeutics is AARD.
-
What is the current stock price of Aardvark Therapeutics?
As of 13-Nov-2026 the stock price of Aardvark Therapeutics is $1.33.
-
What is the current market cap of Aardvark Therapeutics?
The current market capitalization of Aardvark Therapeutics is $29.1M.
-
Who are Aardvark Therapeutics’s competitors?
Galectin Therapeutics, Nimbus Therapeutics, Altimmune, Intellia Therapeutics, and Minerva Neurosciences are some of the 49 competitors of Aardvark Therapeutics.
-
What is Aardvark Therapeutics’s annual earnings per share (EPS)?
Aardvark Therapeutics’s EPS for 12 months was -$3.33.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
